Nicolas SERGEANT is an Inserm Research Director who, from the natural history of Alzheimer’s disease (AD), the development of cell drug-screening models against AD and Tauopathies, and also thanks to a long-term collaboration with the organic chemistry laboratory of Pr. Patricia Melnyk has co-developed small anti-Alzheimer’s drugs that mitigate the pathophysiology of Alzheimer’s disease. One of these is currently in clinical phase II by a PharmD Company. He is also delighted to identify and validate biomarkers to assess neurodegenerative processes in neurological disorders and develop gene therapy using a molecular decoy strategy.